EUVIMEDOpdag EUVIMED
Randomisierte kontrollierte StudieMultizentrische StudieOpen access · CC BY-NC-ND 4.0

Characterization of tirzepatide‐treated patients achieving different glycemic control levels in SURPASS‐AP‐Combo

Yuqian Bao, Lin Han, Liying Du, Linong Ji iD

Obesity · 2024

DOI: 10.1002/oby.24030 ↗

At a glance

Randomisierte kontrollierte Studie in Obesity, 2024. Written by Yuqian Bao and 3 co-authors. Institution: Department of Endocrinology and Metabolism, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai…. Major MEDLINE topics: Diabetes Mellitus, Type 2, Glycated Hemoglobin, Glycemic Control, Blood Glucose. 38 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Eli Lilly and Company.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objective

The study objective was to characterize subgroups of Asia‐Pacific patients with type 2 diabetes who achieved different glycated hemoglobin (HbA1c) targets on tirzepatide treatment.

Methods

This was a post hoc analysis of the SURPASS AP‐Combo study. Baseline characteristics, changes in metabolic markers, and safety were compared between tirzepatide‐treated patients achieving HbA1c

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, Type 2Glycated HemoglobinGlycemic ControlBlood GlucoseHypoglycemic AgentsHumansMaleMiddle AgedFemaleAdultAgedBody Mass IndexTreatment OutcomeGlucagon-Like Peptide-2 ReceptorGastric Inhibitory PolypeptideTirzepatide

Substances

Glycated HemoglobinBlood GlucoseHypoglycemic AgentsTirzepatidehemoglobin A1c protein, humanGlucagon-Like Peptide-2 ReceptorGastric Inhibitory Polypeptide

Authors and institutions

  • Department of Endocrinology and Metabolism, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Eli Lilly Suzhou Pharmaceutical Co. Ltd., Shanghai, China.
  • Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China.

ORCID profiles: Linong Ji

Funding

  • Eli Lilly and Company

Cite

APA

Bao, Y., Han, L., Du, L., & Ji, L. (2024). Characterization of tirzepatide‐treated patients achieving different glycemic control levels in SURPASS‐AP‐Combo. Obesity. https://doi.org/10.1002/oby.24030

Vancouver

Bao Y, Han L, Du L, Ji L. Characterization of tirzepatide‐treated patients achieving different glycemic control levels in SURPASS‐AP‐Combo. Obesity. 2024. doi:10.1002/oby.24030

BibTeX
@article{Bao2024,
  author = {Bao, Yuqian and Han, Lin and Du, Liying and Ji, Linong},
  title = {Characterization of tirzepatide‐treated patients achieving different glycemic control levels in SURPASS‐AP‐Combo},
  journal = {Obesity},
  year = {2024},
  doi = {10.1002/oby.24030}
}
Start for free →